Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.
Esteban E, Fra J, Fernández Y, Corral N, Vieitez JM, Palacio I, de Sande JL, Fernández JL, Muñiz I, Villanueva N, Estrada E, Mareque B, Uña E, Buesa JM, Lacave AJ; Grupo Oncológico del Norte de España (GON). Esteban E, et al. Among authors: lacave aj. Invest New Drugs. 2006 May;24(3):241-8. doi: 10.1007/s10637-005-2478-z. Invest New Drugs. 2006. PMID: 16096704 Clinical Trial.
Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer.
Estaban E, Lacave AJ, Fernández JL, Corral N, Buesa JM, Estrada E, Palacio I, Vieitez JM, Muñiz I, Alvarez E. Estaban E, et al. Among authors: lacave aj. Breast Cancer Res Treat. 1999 Nov;58(2):141-50. doi: 10.1023/a:1006387801960. Breast Cancer Res Treat. 1999. PMID: 10674879 Clinical Trial.
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Esteban E, Modollel A, González de Sande L, Palacio I, Muñiz I, Fernández Y, Corral N, Fra J, Sala M, Vieitez JM, Estrada E, Lacave AJ; Grupo Oncológico del Norte de España. Esteban E, et al. Among authors: lacave aj. Breast Cancer Res Treat. 2003 Aug;80(3):257-65. doi: 10.1023/a:1024985309383. Breast Cancer Res Treat. 2003. PMID: 14503798 Clinical Trial.
Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Esteban E, González de Sande L, Fernández Y, Corral N, Fra J, Muñiz I, Vieitez JM, Palacio I, Fernández JL, Estrada E, Lacave AJ; Grupo Oncológico del Norte de España. Esteban E, et al. Among authors: lacave aj. Ann Oncol. 2003 Nov;14(11):1640-7. doi: 10.1093/annonc/mdg456. Ann Oncol. 2003. PMID: 14581272 Free article. Clinical Trial.
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Gonzalez EE, Villanueva N, Fra J, Berros JP, Jimenez P, Luque M, Muñiz I, Blay P, Fernandez Y, Vieitez JM, Muriel C, Sanmamed M, Coto PP, Izquierdo M, Estrada E, Lacave AJ. Gonzalez EE, et al. Among authors: lacave aj. Invest New Drugs. 2011 Dec;29(6):1459-64. doi: 10.1007/s10637-010-9442-2. Epub 2010 May 13. Invest New Drugs. 2011. PMID: 20464446 Clinical Trial.
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C, Esteban E, Corral N, Fonseca PJ, Luque M, Berros JP, Fernández Y, Blay P, Fra J, Villanueva N, Sanmamed M, Pardo P, Izquierdo M, Vieitez JM, Estrada E, Lacave ÁJ. Muriel C, et al. Among authors: lacave aj. Clin Transl Oncol. 2010 Aug;12(8):562-7. doi: 10.1007/s12094-010-0554-0. Clin Transl Oncol. 2010. PMID: 20709657
69 results